Top

International Journal of Clinical Oncology

Published in:

01-12-2012 | Original Article

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas

Authors: Ichiyo Shibahara, Yukihiko Sonoda, Masayuki Kanamori, Ryuta Saito, Yoji Yamashita, Toshihiro Kumabe, Mika Watanabe, Hiroyoshi Suzuki, Shunsuke Kato, Chikashi Ishioka, Teiji Tominaga

Published in: International Journal of Clinical Oncology | Issue 6/2012

Abstract

Background

The discovery of isocitrate dehydrogenase 1 and 2 gene (IDH1/2) mutations has enabled grade III glioma to be divided into mutated and wild-type IDH1/2 groups, which are known to carry different prognosis and molecular features. However, detailed subgroup analysis of grade III glioma is limited. To address this, we investigated molecular and prognostic features of grade III glioma with and without IDH1/2 mutation.

Methods

We retrospectively analyzed 115 grade III glioma patients. Clinical parameters were obtained from medical records. The mutation of IDH1/2 and TP53 was analyzed by direct sequencing. O⁶-methylguanine methyltransferase gene (MGMT) gene promoter methylation status was determined by methylation-specific polymerase chain reaction. Detection of chromosome copy number changes of 1p, 7p (EGFR), 9p (CDKN2A), 10q (PTEN), and 19q was carried out by multiple ligation-dependent probe amplification. Patients were divided into two groups, mutated IDH1/2 and wild-type IDH1/2, for correlation with the factors analyzed.

Results

In our series, as previously reported, IDH1/2 mutation was an independent prognostic marker for improved progression-free and overall survival (OS) (P < 0.0001 and P < 0.0001, respectively) in patients with grade III gliomas. Subgroup analysis found that incomplete resection, 7p gain, and TP53 mutation were independent prognostic factors of poor outcome in grade III glioma patients with mutated IDH1/2 (P = 0.0092, P = 0.015 and P = 0.026, respectively), while there were none in patients with wild-type IDH1/2.

Conclusions

IDH1/2 gene status was significantly associated with prognosis in grade III gliomas. Subgroup analysis found that poor prognostic factors existed even in patients with IDH1/2 mutation.

Available only for authorised users

Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602PubMedCrossRef

Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812PubMedCrossRef

Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773PubMedCrossRef

Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153PubMedCrossRef

Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100(12):2235–2241PubMedCrossRef

Yan H, Bigner DD, Velculescu V et al (2009) Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69(24):9157–9159PubMedCrossRef

van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16(5):1597–1604PubMedCrossRef

Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347PubMedCrossRef

Levin VA, Hess KR, Choucair A et al (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981–990PubMed

10.

van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24(18):2715–2722PubMedCrossRef

11.

Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154PubMedCrossRef

12.

Houillier C, Mokhtari K, Carpentier C et al (2010) Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas. Neuro Oncol 12(1):2–6PubMedCrossRef

13.

Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100(10):1996–1998PubMedCrossRef

14.

Mashiyama S, Murakami Y, Yoshimoto T et al (1991) Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6(8):1313–1318PubMed

15.

Sonoda Y, Kumabe T, Watanabe M et al (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 151(11):1349–1358CrossRef

16.

Sonoda Y, Yokosawa M, Saito R, et al (2010) O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352–358

17.

Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874–5880PubMedCrossRef

18.

Jeuken J, Sijben A, Alenda C et al (2009) Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19(4):661–671PubMedCrossRef

19.

Jeuken J, Cornelissen S, Boots-Sprenger S et al (2006) Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8(4):433–443PubMedCrossRef

20.

Jeuken JW, Cornelissen SJ, Vriezen M et al (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87(10):1055–1065PubMedCrossRef

21.

Kato H, Kato S, Kumabe T et al (2000) Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6(10):3937–3943PubMed

22.

Kanamori M, Kumabe T, Sonoda Y et al (2009) Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neurooncol 93(2):219–228PubMedCrossRef

23.

Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489PubMed

24.

Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93(16):1246–1256PubMedCrossRef

25.

Dehais C, Laigle-Donadey F, Marie Y et al (2006) Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107(8):1891–1897PubMedCrossRef

26.

Etienne MC, Formento JL, Lebrun-Frenay C et al (1998) Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4(10):2383–2390PubMed

27.

Zhou YH, Tan F, Hess KR et al (2003) The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9(9):3369–3375PubMed

28.

Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474PubMedCrossRef

29.

Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27(34):5743–5750PubMedCrossRef

30.

Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64(19):6892–6899PubMedCrossRef

31.

Ueki K, Ono Y, Henson JW et al (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56(1):150–153PubMed

32.

Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16(6):748–754PubMedCrossRef

33.

Aldape KD, Ballman K, Furth A et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63(7):700–707PubMed

Title: IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
Authors: Ichiyo Shibahara
Yukihiko Sonoda
Masayuki Kanamori
Ryuta Saito
Yoji Yamashita
Toshihiro Kumabe
Mika Watanabe
Hiroyoshi Suzuki
Shunsuke Kato
Chikashi Ishioka
Teiji Tominaga
Publication date: 01-12-2012
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2012
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0323-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

Sperm banking and assisted reproductive outcome in men with cancer: a 10 years’ experience

Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings

Serum total oxidant/antioxidant status and trace element levels in breast cancer patients

Drug-induced interstitial lung disease (DILD) in molecular targeted therapy

Paget’s disease of the vulva: a clinicopathologic institutional review

Current status of DILD in molecular targeted therapies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer